Navamedic - Proxy Solicitation & Information Statement 2025

Navamedic ASA: Notice of extraordinary general meeting on 7 January 2026

Oslo, 12 December 2025: Navamedic ASA ("Navamedic" or the "Company", OSE ticker:

"NAVA") hereby announces that an extraordinary general meeting of Navamedic will

be held on 7 January 2026 at 12:00 CET in order to amend the composition of the

board of directors of the Company.

The extraordinary general meeting of the Company will be held at the Company's

offices at Henrik Ibsens gate 100, 0255 Oslo, Norway. Registration of attendance

must be received no later than 5 January 2026 at 12:00 CET.

Shareholders may vote in advance, or submit a proxy, with or without voting

instructions, by 5 January 2026 at 12:00 CET.

The notice of the extraordinary general meeting, including agenda, proposed

resolutions, registration form and a form of proxy and other information, is

enclosed hereto. Please see the Company's website:

https://navamedic.com/investors/general-meeting/ for other relevant

documentation.

This information is subject to the disclosure requirements in section 5-12 of

the Norwegian Securities Trading Act.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Mobile: +47 951 78 880, e-mail:

Pål Zimmermann Vonen, Director of Group Accounting, Mobile: +47 97 97 92 91, e

About Navamedic

Navamedic ASA is a full-service provider of high-quality healthcare products to

hospitals and pharmacies. Navamedic meets the specific medical needs of patients

and consumers by leveraging its highly scalable market access platform, leading

category competence and local knowledge. Navamedic is present in all the Nordic

countries, the Baltics and Benelux, with sales representation in Greece.

Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock

Exchange (ticker: NAVA). For more information, please visit www.navamedic.com.

AI assistant